Novamind Expands Leadership Team, Accelerating M&A

March 03, 2021

Joseph Braganza joins the organization as SVP, Head of M&A
Previously led M&A at Canadian Addiction Treatment Centres (CATC)

TORONTO, ON / ACCESSWIRE / March 3, 2021 / Novamind Inc., (CSE: NM, OTC: NVMDF) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, announces the appointment of Joseph Braganza to the role of Senior Vice President, Head of M&A. Mr. Braganza joins the senior leadership team with a mandate to lead Novamind’s M&A strategy, accelerating the Company’s expansion plans for its network of clinics, retreats and clinical research sites. Joseph has gained tenure as a M&A specialist and strategist, building sustainable programmatic M&A approaches for high-growth organizations. Leveraging over 20 years of professional experience, Joseph recently led the M&A group as Vice President, Business and Corporate Development at Canadian Addiction Treatment Centres (CATC), a consolidator of outpatient addiction treatment clinics that currently operates over 70 clinics and an inpatient residential treatment facility. Joseph previously held senior M&A roles at People Corp. (acquired by Goldman Sachs Merchant Banking), Rexall Health Solutions (a subsidiary of McKesson Corp. NYSE:MCK) and Deloitte.

“I am deeply committed to Novamind’s vision to scale their operating model for psychedelic medicine,” Braganza commented. “Facilitating greater access to these breakthrough treatments is critical in helping people find new ways to improve their mental health. I look forward to working with the leadership team as we pursue Novamind’s vision.”

Yaron Conforti, CEO and Director of Novamind added, “We’re excited to announce Joseph’s appointment to lead our M&A team. Joseph’s experience acquiring and integrating businesses, combined with his expertise in the mental health sector make him uniquely positioned to contribute to Novamind’s strategic growth plans.”

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.